Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income - MinorityNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Cumberland Pharmaceuticals (CPIX) EBIT (2016 - 2025)

Cumberland Pharmaceuticals (CPIX) has disclosed EBIT for 16 consecutive years, with -$1.4 million as the latest value for Q4 2025.

  • Quarterly EBIT rose 25.56% to -$1.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$2.8 million through Dec 2025, up 56.59% year-over-year, with the annual reading at -$2.8 million for FY2025, 56.59% up from the prior year.
  • EBIT hit -$1.4 million in Q4 2025 for Cumberland Pharmaceuticals, up from -$2.0 million in the prior quarter.
  • In the past five years, EBIT ranged from a high of $1.3 million in Q1 2025 to a low of -$6.2 million in Q4 2023.
  • Historically, EBIT has averaged -$1.6 million across 5 years, with a median of -$1.5 million in 2021.
  • Biggest five-year swings in EBIT: tumbled 4591.4% in 2024 and later soared 169.12% in 2025.
  • Year by year, EBIT stood at -$4.4 million in 2021, then soared by 47.68% to -$2.3 million in 2022, then plummeted by 171.28% to -$6.2 million in 2023, then skyrocketed by 70.19% to -$1.8 million in 2024, then rose by 25.56% to -$1.4 million in 2025.
  • Business Quant data shows EBIT for CPIX at -$1.4 million in Q4 2025, -$2.0 million in Q3 2025, and -$747478.0 in Q2 2025.